Morán Segundo, Duque-López Ma Ximena, Salmerón-Castro Jorge, Rodríguez-Leal Gustavo, Martínez-Salgado Homero, Uribe Misael
Laboratorio de Investigacíon en Gastroenterologia, Hospital de Pediatría, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Arch Med Res. 2003 May-Jun;34(3):194-9. doi: 10.1016/S0188-4409(03)00025-0.
A total of 1,255 subjects attending a private health care facility in Mexico City were studied to evaluate the association of serum concentration of Apo A-I and Apo B with presence of gallbladder disease (gallstones or cholecystectomy).
A cross-sectional study was carried out. All participants provided data on sociodemographic status and previous diagnoses of type 2 diabetes, hypertension, cardiovascular events, alcohol consumption, and smoking habits. Women additionally reported their obstetric-gynecologic history. Weight and height were measured; liver and biliary tract ultrasound assessed gallbladder disease. Plasma levels of total cholesterol, triglycerides, high-density lipoproteins (HDL) cholesterol, and apolipoproteins A-I (Apo A-I) and B (Apo B) were determined after a 12-h fasting period.
In multivariate models, Apo A-I > or = 120 mg/dL was positively associated with gallbladder disease with odds ratio (OR) = 1.64, 95% confidence interval (95% CI) = 1.03-2.62, whereas Apo B > or = 120 mg/dL showed an inverse association (OR = 0.71, 95% CI = 0.48-1.05). Ratio of Apo B/Apo A-I > or = 1 was inversely associated with risk of gallbladder disease (OR = 0.54, 95% CI = 0.37-0.80). All models were adjusted for age, gender, body mass index (BMI), previous diagnosis of type 2 diabetes, triglycerides, alcohol consumption, tobacco, and contraceptive use, as well as for total cholesterol in HDL-cholesterol and Apo A-I models.
Our results suggested the relationship between serum concentration of apolipoproteins and gallbladder disease. These findings support the hypothesis of increased biliary catabolism of cholesterol in subjects with gallbladder disease characterized by lower Apo B and higher Apo A-I serum concentrations.
对墨西哥城一家私立医疗机构的1255名受试者进行了研究，以评估载脂蛋白A-I（Apo A-I）和载脂蛋白B（Apo B）的血清浓度与胆囊疾病（胆结石或胆囊切除术）之间的关联。
开展了一项横断面研究。所有参与者提供了关于社会人口统计学状况以及2型糖尿病、高血压、心血管事件、饮酒和吸烟习惯既往诊断情况的数据。女性还报告了她们的妇产科病史。测量了体重和身高；通过肝脏和胆道超声评估胆囊疾病。在禁食12小时后测定了总胆固醇、甘油三酯、高密度脂蛋白（HDL）胆固醇以及载脂蛋白A-I（Apo A-I）和B（Apo B）的血浆水平。
在多变量模型中，Apo A-I≥120mg/dL与胆囊疾病呈正相关，优势比（OR）=1.64，95%置信区间（95%CI）=1.03 - 2.62，而Apo B≥120mg/dL呈负相关（OR = 0.71，95%CI = 0.48 - 1.05）。Apo B/Apo A-I≥1与胆囊疾病风险呈负相关（OR = 0.54，95%CI = 0.37 - 0.80）。所有模型均针对年龄、性别、体重指数（BMI）、2型糖尿病既往诊断情况、甘油三酯、饮酒、吸烟、避孕药使用情况以及HDL胆固醇和Apo A-I模型中的总胆固醇进行了校正。
我们的结果提示了载脂蛋白血清浓度与胆囊疾病之间的关系。这些发现支持了以下假说：在以较低的Apo B和较高的Apo A-I血清浓度为特征的胆囊疾病患者中，胆固醇的胆道分解代谢增加。
